US Bioservices selected by Clovis Oncology to dispense RUBRACA

December 20, 2016


Frisco, Texas – US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, announced today it has been selected by Clovis Oncology to dispense RUBRACA® (rucaparib). RUBRACA was approved by the U.S. Food and Drug Administration on December 19, 2016, for the treatment of patients with ovarian cancer who have deleterious BRCA-mutated tumors – inclusive of both germline and somatic BRCA mutations – and have been treated with two or more chemotherapies.

Ovarian cancer is the fifth-leading cause of cancer-related death among women in the United States and the deadliest of the gynecologic cancers[1]. In 2016, an estimated 22,280 women will be diagnosed with ovarian cancer, according to the American Cancer Society.

“We are pleased to support an advanced treatment option for patients diagnosed with ovarian cancer,” said Aaron Sathre, senior vice president of Client Growth and Development for US Bioservices. “Our collaborative approach with providers will allow us to best support RUBRACA patients throughout their treatment journey.”

As an independent specialty pharmacy with a dedicated Oncology Patient Support Team, US Bioservices provides high-touch clinical care that is specific to the patient’s needs, conditions and therapies. US Bioservices’ multidisciplinary teams are organized to develop long-standing, collaborative relationships with oncologists, resulting in more integrated care for patients and caregivers.

RUBRACA is a limited distribution medication that is only available from select specialty pharmacies. Physicians may submit prescriptions to US Bioservices via phone (877.757.0667), fax (888.899.0067),